Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Renal Care

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Acute Therapy

    Organ support and blood purification therapies are essential to improving patient outcomes in the ICU.

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx Therapy

    HDx - also known as expanded hemodialysis - is an innovative therapy that effectively targets the removal of large middle molecules.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro

Learn More
  • "Pro-inflammatory cytokines IL-1β and TNF-α identified as key uremic triggers for calcific differentiation of MSC, progenitor cells implicated in vascular regeneration, supporting anti-inflammatory strategies in CKD patients to restore vascular regenerative capacity and prevent excessive vascular damage.
    “Top 4” toxins identified in our screening approach, IL-1β, TNF-α, FGF-2, and PTH1-84, are “middle-sized molecules” poorly removed by conventional dialysis with high-flux membranes. Selective medium cut-off (MCO) membranes are novel therapeutic strategy"